The efficacy of pancreatic juice cytology with liquid-based cytology for evaluating malignancy in patients with intraductal papillary mucinous neoplasm

[1] Tanaka M(2017)Revisions of international consensus Fukuoka guidelines for the management of IPMN of the pancreas Pancreatology 17 738-753

[2] Fernández-Del Castillo C(2016)The safety and benefit of pancreatic juice cytology under ERCP in IPMN patients Pancreatology 16 1020-1027

[3] Kamisawa T(2014)International consensus guidelines parameters for the prediction of malignancy in intraductal papillary mucinous neoplasm are not properly weighted and are not cumulative HPB 16 929-935

[4] Yoshioka T(2012)The carcinoembryonic antigen level in pancreatic juice and mural nodule size are predictors of malignancy for branch duct type intraductal papillary mucinous neoplasms of the pancreas Ann Surg 255 517-522

[5] Shigekawa M(2016)Mural nodule of 10 mm or larger as predictor of malignancy for intraductal papillary mucinous neoplasm of the pancreas: pathological and radiological evaluations Pancreatology 16 441-448

[6] Yamai T(2011)Size of mural nodule as an indicator of surgery for branch duct intraductal papillary mucinous neoplasm of the pancreas during follow-up J Gastroenterol 46 657-663

[7] Roch AM(2012)Endoscopic ultrasonographic findings predict the risk of carcinoma in branch duct intraductal papillary mucinous neoplasms of the pancreas Pancreatology. 12 141-145

[8] Ceppa EP(2013)Predictors of malignancy in intraductal papillary mucinous neoplasm of the pancreas. Analysis of 310 pancreatic resection patients at multiple high-volume centers Pancreas. 42 883-888

[9] DeWitt JM(2014)Natural history of branch duct intraductal papillary mucinous neoplasm with mural nodules: a Japan pancreas society multicenter study Pancreas 43 532-538

[10] Hirono S(2016)Development and potential utility of a new scoring formula for prediction of malignant intraductal papillary mucinous neoplasm of the pancreas Pancreas 45 1227-1232

[1] Tanaka M(2017)Revisions of international consensus Fukuoka guidelines for the management of IPMN of the pancreas Pancreatology 17 738-753

[2] Fernández-Del Castillo C(2016)The safety and benefit of pancreatic juice cytology under ERCP in IPMN patients Pancreatology 16 1020-1027

[3] Kamisawa T(2014)International consensus guidelines parameters for the prediction of malignancy in intraductal papillary mucinous neoplasm are not properly weighted and are not cumulative HPB 16 929-935

[4] Yoshioka T(2012)The carcinoembryonic antigen level in pancreatic juice and mural nodule size are predictors of malignancy for branch duct type intraductal papillary mucinous neoplasms of the pancreas Ann Surg 255 517-522

[5] Shigekawa M(2016)Mural nodule of 10 mm or larger as predictor of malignancy for intraductal papillary mucinous neoplasm of the pancreas: pathological and radiological evaluations Pancreatology 16 441-448

[6] Yamai T(2011)Size of mural nodule as an indicator of surgery for branch duct intraductal papillary mucinous neoplasm of the pancreas during follow-up J Gastroenterol 46 657-663

[7] Roch AM(2012)Endoscopic ultrasonographic findings predict the risk of carcinoma in branch duct intraductal papillary mucinous neoplasms of the pancreas Pancreatology. 12 141-145

[8] Ceppa EP(2013)Predictors of malignancy in intraductal papillary mucinous neoplasm of the pancreas. Analysis of 310 pancreatic resection patients at multiple high-volume centers Pancreas. 42 883-888

[9] DeWitt JM(2014)Natural history of branch duct intraductal papillary mucinous neoplasm with mural nodules: a Japan pancreas society multicenter study Pancreas 43 532-538

[10] Hirono S(2016)Development and potential utility of a new scoring formula for prediction of malignant intraductal papillary mucinous neoplasm of the pancreas Pancreas 45 1227-1232